Samsung Bioepis
Samsung Biologics Snaps Up Biogen’s Stake in Samsung Bioepis for $2.3 Billion, Assuming Full Control of Biosimilar Venture
2022-01-28
Korea Made Humira Biosimilar Begins Sales in Australia, Marks its Presence in Third Overseas Market
2021-03-31